多発性骨髄腫の診療指針　第5版

出版社： 文光堂
著者：
発行日： 2020-09-26
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784830620614
電子書籍版： 2020-09-26 （第5版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,520 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,520 円(税込)

購入する

商品紹介

ゲノム解析の進歩などにより基礎研究の知見が蓄積され，新たな薬剤や併用療法の進歩が著しい多発性骨髄腫とその類縁疾患．本書では，多発性骨髄腫の定義から臨床所見，診断基準，治療，類縁疾患の診断と治療までを，最新の知見を踏まえて解説する．第5版では，“臨床現場で気軽に手に取り，参照できるガイドライン”を目指し，診療に関する膨大な情報を図表で整理しつつ，治療アルゴリズムや開発中の薬剤など，最新の動向も取り入れ紹介している．巻末には3,022例の臨床データをまとめた「資料編」を掲載．

目次

  • I　定義および疫学
    　1　定　義
    　2　疫　学
    　　1）罹患率と疫学
    　　2）診断時の年齢と性
    　　3）多発性骨髄腫の死亡数と死亡率

    II　臨床所見と初診時検査
    　1　臨床所見
    　　1）骨痛
    　　2）貧血
    　　3）腎障害
    　　4）高カルシウム血症
    　　5）易感染性
    　　6）神経症状
    　　7）その他
    　2　初診時検査
    　　1）末梢血・血液生化学
    　　2）M蛋白
    　　3）骨髄検査
    　　［コラム］多段階発がん過程
    　　4）骨病変の画像検査

    III　診断基準と病期分類
    　1　診断基準
    　　1）多発性骨髄腫
    　　2）くすぶり型多発性骨髄腫
    　　3）意義不明の単クローン性ガンマグロブリン血症（MGUS）
    　　4）孤立性形質細胞腫
    　　5）POEMS症候群
    　　6）全身性ALアミロイドーシス
    　2　病期分類

    IV　治　療
    　1　治療開始時期
    　2　治療効果判定
    　3　多発性骨髄腫患者に対する治療アルゴリズム
    　　1）移植適応のある初発多発性骨髄腫患者
    　　2）移植非適応の初発多発性骨髄腫患者
    　　3）再発・難治性骨髄腫患者
    　　［用語解説］risk-adapted strategy
    　4　PI・IMiDs・抗体医薬の併用療法のコンセプト
    　5　初期治療
    　　1）移植適応例に対する初期治療
    　　2）移植非適応例に対する初期治療
    　　3）高齢者（frail）に対する治療
    　6　維持療法
    　　1）THAL維持療法
    　　2）LEN維持療法
    　　3）BOR維持療法
    　　4）IXA維持療法
    　　［コラム］LEN維持療法後の二次発がん
    　7　再発・治療抵抗性骨髄腫の治療
    　　1）再発・進行後の治療方針
    　　2）再発・治療抵抗例における治療レジメン
    　　3）再発・治療抵抗例における移植療法
    　　4）再発・治療抵抗例における治療選択
    　8　開発中の薬剤
    　　1）モノクローナル抗体（MoAb）
    　　2）分子標的薬
    　　3）CAR-T療法
    　9　研究的治療─同種移植（ミニ移植を含む）
    　　1）骨髄破壊的前処置による同種移植
    　　2）用量減量前処置による同種移植
    　　3）タンデムHDC-ASCT/ミニ移植
    　　4）同種移植後の新規薬剤
    　10　放射線療法
    　　1）疼痛緩和を目的とする場合
    　　2）腫瘍の消失（縮小）を目的とする場合
    　11　合併症に対する治療
    　　1）骨病変
    　　［用語解説］骨吸収抑制薬関連顎骨壊死（ARONJ）
    　　2）高カルシウム血症
    　　3）貧血
    　　4）腎不全
    　　5）感染症
    　　6）神経障害
    　　7）その他，過粘稠度症候群など

    V　類縁疾患
    　1　POEMS症候群（Crow-Fukase症候群，高月病）
    　　1）所見と診断基準
    　　2）治療
    　2　原発性アミロイドーシス
    　　1）アミロイドーシスの原因・分類
    　　2）原発性アミロイドーシス
    　3　MGRS
    　　1）MGRSの概念
    　　2）MGRSの検査と診断
    　　3）MGRSの治療戦略
    　4　原発性マクログロブリン血症
    　　1）定義と診断
    　　2）疫学
    　　3）遺伝子変異
    　　4）先行病態と治療開始基準
    　　5）治療

    VI　患者に対する情報提供および支援活動

    文　献
    資料編
    索　引

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 定義および疫学

P.1 掲載の参考文献
1) 国立がん研究センターがん情報サービス「がん登録・統計」 : https://ganjoho.jp/reg_stat/statistics/brochure/monitoring.html (https://ganjoho.jp/reg_stat/statistics/stat/summary.html)
 
2) Phekoo KJ, et al : A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 127 : 299-304, 2004.
 
3) Velez R, et al : Incidence of multiple myeloma in Great Britain, Sweden, and Malmo, Sweden : the impact of difference in case ascertainment on observed incidence trends. BMJ Open 6 : e009584, 2016.
 
4) Kyle RA, et al : Incidence of multiple myeloma in Olmsted County Minnesota : Trend over 6 decades. Cancer 101 : 2667-2674, 2004.
PubMed
5) Waxman AJ, et al : Racial disparities in incidence and outcome in multiple myeloma : a population based study. Blood 116 : 5501-5506, 2010.
PubMed
6) Kim K, et al : Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. Am J Hematol 89 : 751-756, 2014.
PubMed
7) Landgren O, et al : Monoclonal gammopathy of undetermined significance (MGUS) consistently precede multiple myeloma : a prospective study. Blood 113 : 5412-5417, 2009.
 
8) Weiss BM, et al : A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113 : 5418-5422, 2009.
PubMed
9) Greenberg AJ, et al : Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia 26 : 609-614, 2012.
PubMed
10) Ozaki S, et al : Trends of survival in patients with multiple myeloma in Japan : a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J 5 : e349, 2015.
PubMed

II 臨床所見と初診時検査

P.5 掲載の参考文献
1) 日本骨髄腫学会, 編 : 資料編. 多発性骨髄腫の診療指針, 第5版, 文光堂, 2020.
 
2) Rajkumar SV, et al : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 : e538-548, 2014.
 
3) Rajkumar SV, et al : Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ Book 35 : e418-423, 2016.
PubMed
4) Silvestris F, et al : Negative regulation of erythroblast maturation by Fas-L (+) /TRAIL (+) highly malignant plasma cells : a major pathogenic mechanism of anemia in multiple myeloma. Blood 99 : 1305-1313, 2002.
 
5) Dimopoulos MA, et al : Renal impairment in patients with multiple myeloma : a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28 : 4976-4984, 2010.
 
6) Durie BG & Salmon SE : A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36 : 842-854, 1975.
PubMed
7) Greipp PR, et al : International staging system for multiple myeloma. J Clin Oncol 23 : 3412-3420, 2005.
PubMed
8) Palumbo A, et al : Revised International Staging System for Multiple Myeloma : A Report From International Myeloma Working Group. J Clin Oncol 33 : 2863-2869, 2015.
 
9) Dimopoulos M, et al : Consensus recommendations for standard investigative workup : report of the International Myeloma Workshop Consensus Panel 3. Blood 117 : 4701-4705, 2011.
PubMed
10) International Myeloma Working Group : Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders : a report of the International Myeloma Working Group. Br J Haematol 121 : 749-757, 2003.
 
11) Fernandez de Larrea C, et al : Plasma cell leukemia : consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27 : 780-791, 2013.
 
12) Pham A, et al : Multiple myeloma-induced hyperammonemic encephalopathy : an entity associated with high in-patient mortality. Leuk Res 37 : 1229-1232, 2013.
PubMed
13) Sosnoff DR, et al : Salivary amylase-producing multiple myeloma : case report and review of the current literature. J Clin Oncol 31 : e309-e311, 2013.
PubMed
14) Endo S, et al : MUC1/KL-6 expression confers an aggressive phenotype upon myeloma cells. BBRC 507 : 246-252, 2018.
PubMed
15) Keren DF, et al : Strategy to diagnose monoclonal gammopathies in serum : high-resolution electrophoresis, immunofixation, and Kappa/lambda quantification. Clin Invest 34 : 2196-2201, 1988.
 
16) Durie BG, et al : International uniform response criteria for multiple myeloma. Leukemia 20 : 1467-1473, 2006.
PubMed
17) Katzmann JA, et al : Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains : relative sensitivity for detection of monoclonal light chains. Clin Chem 48 : 1437-1444, 2002.
PubMed
18) Dispenzieri A, et al : International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23 : 215-224, 2009.
 
19) Kumar S, et al : International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17 : e328-346, 2016.
 
20) Katzmann JA, et al : Screening panels for detection of monoclonal gammopathies. Clin Chem 55 : 1517-1522, 2009.
PubMed
21) Rajkumar SV, et al : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 : e538-548, 2014.
 
22) Kyrtsonis MC, et al : Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 137 : 240-243, 2007.
PubMed
23) Dejoie T, et al : Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood 128 : 2941-2948, 2016.
 
24) Dispenzieri A, et al : Appraisal of immunoglobulin free light chain as a marker of response. Blood 111 : 4908-4915, 2008.
 
25) Dejoie T, et al : Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. Haematologica 101 : 356-362, 2016.
PubMed
26) Brioli A, et al : Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood 123 : 3414-3419, 2014.
PubMed
27) Paiva B, et al : New criteria for response assessment : role of minimal residual disease in multiple myeloma. Blood 125 : 3059-3068. 2015.
PubMed
28) Arana P, et al : Prognostic value of antigen expression in multiple myeloma : a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia 32 : 971-978, 2018.
 
29) Flores-Montero J, et al : Immunophenotype of normal vs. myeloma plasma cells : Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom 90 : 61-72, 2016.
PubMed
30) Flores-Montero J, et al : Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31 : 2094-2103, 2017.
PubMed
31) Takamatsu H, et al : Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int J Hematol 109 : 377-381, 2019.
PubMed
32) Blum A, et al : Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma. Sci Rep 9 : 2922, 2019.
PubMed
33) Taniwaki M, et al : Interphase and metaphase detection of the breakpoint of 14q32 translocations in B-cell malignancies by double-color fluorescence in situ hybridization. Blood 85 : 3223-3228, 1995.
 
34) Rajan AM & Rajkumar SV : Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J 5 : e365, 2015.
PubMed
35) Boyd KD, et al : A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS : analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26 : 349-355, 2012.
 
36) Manier S, et al : Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 14 : 100, 2016.
PubMed
37) Santra M, et al : A subset of multiple myeloma harboring the t (4 ; 14) (p16 ; q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 101 : 2374-2376, 2003.
 
38) Carrasco DR, et al : High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9 : 313-325, 2006.
PubMed
39) Walker BA, et al : Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 132 : 587, 2018.
PubMed
40) Hanamura I, et al : Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization : incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108 : 1724-1732, 2006.
PubMed
41) Grzasko N, et al : Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematol Oncol 31 : 41-48, 2013.
PubMed
42) Chapman MA, et al : Initial genome sequencing and analysis of multiple myeloma. Nature 471 : 467-472, 2011.
PubMed
43) Chretien M-L, et al : Understanding the role of hyperdiploidy in myeloma prognosis : which trisomies really matter? Blood 126 : 2713, 2015.
PubMed
44) Shah V, et al : Prediction of outcome in newly diagnosed myeloma : a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia 32 : 102, 2017.
PubMed
45) Walker BA, et al : A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 33 : 159-170, 2019.
PubMed
46) Palumbo A, et al : Revised International Staging System for Multiple Myeloma : A Report From International Myeloma Working Group. J Clin Oncol 33 : 2863-2869, 2015.
 
47) Sonneveld P, et al : Treatment of multiple myeloma with high-risk cytogenetics : a consensus of the International Myeloma Working Group. Blood 127 : 2955-2962, 2016.
 
48) Walker BA, et al : Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 121 : 3413-3419, 2013.
 
49) Greaves M & Maley CC : Clonal evolution in cancer. Nature 481 : 306-313, 2012.
PubMed
50) Alexandrov LB, et al : Signatures of mutational processes in human cancer. Nature 500 : 415, 2013.
PubMed
51) Walker BA, et al : APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun 6 : 6997, 2015.
PubMed
52) Pawlyn C, et al : Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma : a role for PARP inhibition? Leukemia 32 : 1561-1566, 2018.
PubMed
53) Bolli N, et al : Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5 : 2997, 2014.
PubMed
54) Paiva B, et al : New criteria for response assessment : role of minimal residual disease in multiple myeloma. Blood 125 : 3059-3068, 2015.
PubMed
55) 高松博幸 : 多発性骨髄腫における微小残存病変検査とその臨床的意義. 臨床血液 59 : 293-301, 2018.
 
56) Kalina T, et al : Quality assessment program for EuroFlow protocols : summary results of fouryear (2010-2013) quality assurance rounds. Cytometry A 87 : 145-156, 2015.
 
57) Stetler-Stevenson M, et al : Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin cytom 90 : 26-30, 2016.
PubMed
58) Flores-Montero J, et al : Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31 : 2094-2103, 2017.
PubMed
59) Kumar S, et al : International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17 : e328-346, 2016.
 
60) Takamatsu H, et al : Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int J Hematol 109 : 377-381, 2019.
PubMed
61) Facon T, et al : Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med 380 : 2104-2115, 2019.
PubMed
62) Mateos MV, et al : Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med 378 : 518-528, 2018.
PubMed
63) Takamatsu H, et al : Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. Ann Oncol 28 : 2503-2510, 2017.
PubMed
64) Perrot A, et al : Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132 : 2456-2464, 2018. 65) Rajkumar SV, et al : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 : e538-548, 2014.
 
65) Rajkumar SV, et al : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 : e538-548, 2014.
 
66) Iida S, et al : JSH practical guidelines for hematological malignancies, 2018 : III. Myeloma-1. Multiple myeloma (MM). Int J Hematol 109 : 509-538, 2019.
PubMed
67) Moreau P, et al : Multiple myeloma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28 Suppl : iv52-61, 2017.
PubMed
68) Mikhael J, et al : Treatment of Multiple Myeloma : ASCO and CCO Joint Clinical Practice Guideline Summary. J Oncol Pract 15 : 279-286, 2019.
 
69) Lutje S, et al : Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol 88 : 1161-1168, 2009.
PubMed
70) Durie BG, et al : Whole-body 18F-FDG PET identifies high-risk myeloma. J Nucl Med 43 : 1457-1463, 2002.
PubMed

III 診断基準と病期分類

P.21 掲載の参考文献
1) International Myeloma Working Group : Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders : a report of the International Myeloma Working Group. Br J Haematol 121 : 749-757, 2003.
 
2) Mateos MV, et al : Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 369 : 438-447, 2013.
PubMed
3) Hillengass J, et al : International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20 : e302-312, 2019.
 
4) Rajkumar SV, et al : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 : e538-548, 2014.
 
5) Rajkumar SV, et al : Diagnosis of smoldering multiple myeloma. N Engl J Med 365 : 474-475, 2011.
PubMed
6) Larsen JT, et al : Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 27 : 941-946, 2013.
PubMed
7) Hillengass J, et al : Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28 : 1606-1610, 2010.
PubMed
8) Greipp PR, et al : International staging system for multiple myeloma. J Clin Oncol 23 : 3412-3420, 2005.
PubMed
9) Palumbo A, et al : Revised International Staging System for multiple myeloma : a report from International Myeloma Working Group. J Clin Oncol 33 : 2863-2869, 2015.
 
10) Dimopoulos MA, et al : High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 115 : 931-935, 1991.
PubMed
11) Terpos E, et al : High serum lactate dehydrogenase adds prognostic value to the international tagging system even in the era of novel agents. Eur J Haematol 85 : 114-119, 2010.
 
12) Ozaki S, et al : Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. Ann Hematol 98 : 1703-1711, 2019.
PubMed
13) Durie BG, et al : A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36 : 842-854, 1975.
PubMed
14) Durie BG : The role of anatomic and functional staging in multiple myeloma : description of Durie/Salmon plus staging system. Eur J Cancer 42 : 1539-1543, 2006.
PubMed
15) Rajkumar SV, et al : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 : e538-548, 2014.
 

IV 治療

P.31 掲載の参考文献
1) International Myeloma Working Group : Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders : a report of the International Myeloma Working Group. Br J Haematol 121 : 749-757, 2003.
 
2) Rajkumar SV, et al : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 : e538-548, 2014.
 
3) Rajkumar SV, et al : Diagnosis of smoldering multiple myeloma. N Engl J Med 365 : 474-475, 2011.
PubMed
4) Larsen JT, et al : Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 27 : 941-946, 2013.
PubMed
5) Hillengass J, et al : Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28 : 1606-1610, 2010.
PubMed
6) Blade J, et al : Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102 : 1115-1123, 1998.
 
7) Durie BG, et al : International uniform response criteria for multiple myeloma. Leukemia 20 : 1467-1473, 2006.
PubMed
8) Rajkumar SV, et al : Consensus recommendations for the uniform reporting of clinical trials : report of the International Myeloma Workshop Consensus Panel 1. Blood 117 : 4691-4695, 2011.
PubMed
9) Rawstron AC, et al : Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma : impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 31 : 2540-2547, 2013.
PubMed
10) Martinez-Lopez J, et al : Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123 : 3073-3079, 2014.
PubMed
11) Munshi NC, et al : Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma : A Meta-analysis. JAMA Oncol 3 : 28-35, 2017.
PubMed
12) Cavo M, et al : Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders : a consensus statement by the International Myeloma Working Group. Lancet Oncol 18 : e206-217, 2017.
 
13) Kumar S, et al : International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17 : e328-346, 2016.
 
14) Dispenzieri A, et al : International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23 : 215-224, 2009.
 
15) Dimopoulos MA, et al : International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 34 : 1544-1557, 2016.
 
16) Koreth J, et al : High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma : a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 13 : 183-196, 2007.
PubMed
17) Martinez-Lopez J, et al : Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118 : 529-534, 2011.
PubMed
18) Perrot A, et al : Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132 : 2424-2425, 2018.
 
19) Gay F, et al : Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents : analysis of 1175 patients. Blood 117 : 3025-3031, 2011.
PubMed
20) Sonneveld P, et al : Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma : a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31 : 3279-3287, 2013.
PubMed
21) Moreau P, et al : Comparison of 200mg/m2 melphalan and 8 Gy total body irradiation plus 140mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma : final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99 : 731-735, 2002.
 
22) Stadtmauer EA, et al : Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma : results of the BMT CTN0702 trial. J Clin Oncol 37 : 589-597, 2019.
 
23) McCarthy PL, et al : Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma : a meta-analysis. J Clin Oncol 35 : 3269-3271, 2017.
 
24) Dimopoulos MA, et al : Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomized, placebo-controlled phase 3 trial. Lancet 393 : 253-264, 2019.
PubMed
25) Dimopoulos MA, et al : Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 378 : 518-528, 2018.
PubMed
26) Facon T, et al : Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380 : 2104-2115, 2019.
PubMed
27) San Miguel JF, et al : Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 31 : 448-455, 2013.
PubMed
28) Fayers PM, et al : Thalidomide for previously untreated elderly patients with multiple myeloma : meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118 : 1239-1247, 2011.
PubMed
29) Benboubker L, et al : Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371 : 906-917, 2014.
PubMed
30) Rajkumar SV, et al : Lenalidomide plus high-dose dexamethasone versus lenalidomide plus lowdose dexamethasone as initial therapy for newly diagnosed multiple myeloma : an open-label randomized controlled trial. Lancet Oncol 11 : 29-37, 2010.
 
31) Cook G, et al : High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse【Intensive trial】) : a randomized open-label, phase 3 trial. Lancet Oncol 15 : 874-885, 2014.
 
32) Raje N, et al : Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380 : 1726-1737, 2019.
PubMed
33) Lonial S, et al : Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2) : a two-arm, randomized, open-label, phase 2 study. Lancet Oncol 21 : 207-221, 2020.
 
34) Topp MS, et al : Anti-B-cell maturation antigen BiTE molecule AMG420 induces responses in multiple myeloma. J Clin Oncol 38 : 775-783, 2020.
 
35) mSMART : Stratification for myeloma & risk-adapted therapy. (http://www.msmart.org)
 
36) Sonneveld P, et al : Treatment of multiple myeloma with high-risk cytogenetics : a consensus of the International Myeloma Working Group. Blood 127 : 2955-2962, 2016.
 
37) Gavriatopoulou M, et al : How I treat elderly patients with plasma cell dyscrasias. Aging 10 : 4248-4268, 2018.
 
38) Fricker LD : Proteasome Inhibitor Drugs. Annu Rev Pharmacol Toxicol 60 : 457-476, 2020
PubMed
39) Chaidos A, et al : Clinical drug resistance linked to interconvertible phenotypes and functional states of tumor-propagating cells in multiple myeloma. Blood 121 : 318-328, 2013.
PubMed
40) Leung-Hagesteijn C, et al : Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 24 : 289-304, 2013.
PubMed
41) Kronke J, et al : Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343 : 301-305, 2014.
PubMed
42) Jourdan M, et al : Differential effects of lenalidomide during plasma cell differentiation. Oncotarget 7 : 28096-28111, 2016.
PubMed
43) Kikuchi J, et al : Myeloma cells are activated in bone marrow microenvironment by the CD180/MD-1 complex which senses lipopolysaccharide. Cancer Res 78 : 1766-1778, 2018.
 
44) Zhu YX, et al : Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood 124 : 536-545, 2014.
PubMed
45) Shi CX, et al : Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma. Haematologica 100 : e315-317, 2015.
PubMed
46) Kikuchi J, et al : Suitable drug combination with bortezomib for multiple myeloma under stromafree conditions and in contact with fibronectin or bone marrow stroma. Int J Hematol 99 : 726-736, 2014.
PubMed
47) Cao Y, et al : Treatment outcomes in patients with newly diagnosed multiple myeloma who are ineligible for stem-cell transplantation : Systemic review and network meta-analysis. Clin Lymphoma Myeloma Leuk 19 : e478-488, 2019.
 
48) Harousseau JL, et al : Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma : results of the IFM 2005-01 phase III trial. J Clin Oncol 28 : 4621-4629, 2010.
PubMed
49) Sonneveld P, et al : Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma : results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 30 : 2946-2955, 2012.
 
50) Rosinol L, et al : Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma : a randomized phase 3 PETHEMA/GEM study. Blood 120 : 1589-1596, 2012.
PubMed
51) Sonneveld P, et al : Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma : a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31 : 3279-3287, 2013.
PubMed
52) Durie B, et al : Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777) : a randomised, open-label, phase 3 trial. Lancet 389 : 519-527, 2017.
PubMed
53) Mai EK, et al : Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia 29 : 1721-1729, 2015.
PubMed
54) Zonder JA, et al : Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma : a randomized Southwest Oncology Group (S0232). Blood 116 : 5838-5841, 2010.
 
55) Rajkumar SV, et al : Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma : an open-label randomized controlled trial. Lancet Oncol 11 : 29-37, 2010.
PubMed
56) Kumar S, et al : Impact of lenalidomide therapy on stem cell mobilization and engraftment postperipheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21 : 2035-2042, 2007.
 
57) Mark T, et al : Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 14 : 795-798, 2008.
 
58) DiPersio JF, et al : Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113 : 5720-5726, 2009.
 
59) Ri M, et al : Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma. Int J Hematol 106 : 562-572, 2017.
PubMed
60) Martinez-Lopez J, et al : Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118 : 529-534, 2011.
PubMed
61) Van de Velde HJ, et al : Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Heamatologica 92 : 1399-1406, 2007.
PubMed
62) Palumbo A, et al : Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371 : 895-905, 2014.
PubMed
63) Gay F, et al : Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma : a randomised, multicentre, phase 3 trial. Lancet Oncol 16 : 1617-1629, 2015.
PubMed
64) Attal M, et al : Autologous transplantation for multiple myeloma in the era of new drugs : a phase III study of the Intergroupe Francophone du Myelome (IFM/DFCI 2009 trial). Blood 126 : 391, 2015.
 
65) Cavo M, et al : Double Autologous Stem Cell Transplantation Significantly Prolongs Progression-Free Survival and Overall Survival in Comparison with Single Autotransplantation in Newly Diagnosed Multiple Myeloma : An Analysis of Phase 3 EMN02/HO95 Study. Blood 130 Suppl 1 : 401, 2017.
 
66) Stadtmauer EA, et al : Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with len maintenance (ACM), tandem autoHCT with len maintenance (TAM) and autoHCT with len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM) : primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702-StaMINA Trial). Blood 128 : LBA-1, 2016.
 
67) San Miguel JF, et al : Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359 : 906-917, 2008.
PubMed
68) San Miguel JF, et al : Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 31 : 448-455, 2013.
PubMed
69) Mateos MV, et al : Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med 378 : 518-528, 2018.
PubMed
70) Mateos MV, et al : Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE) : a randomised, open-label, phase 3 trial. Lancet 395 : 132, 2020.
PubMed
71) Benboubker L, et al : Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371 : 906-917, 2014.
PubMed
72) Facon T, et al : Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131 : 301-310, 2018.
PubMed
73) Durie BG, et al : Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777) : a randomised, open-label, phase 3 trial. Lancet 389 : 519-527, 2017.
PubMed
74) O'Donnell EK, et al : A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol 182 : 222-230, 2018.
 
75) Elizabeth K, et al : Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma. Blood 134 (suppl 1) : 3178, 2019.
 
76) Facon T, et al : Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med 380 : 2104-2115, 2019.
PubMed
77) Bahlis N, et al : Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant : Updated Analysis of Maia. Blood 134 (suppl 1) : 1875, 2019.
 
78) Gay F, et al : Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents : analysis of 1175 patients. Blood 117 : 3025-3031, 2011.
PubMed
79) Palumbo A, et al : Geriatric assessment predicts survival and toxicities in elderly myeloma patients : an International Myeloma Working Group report. Blood 125 : 2068-2074, 2015.
 
80) Engelhardt M, et al : A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 102 : 910-921, 2017.
 
81) Milani P, et al : N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol 91 : 1129-1134, 2016.
PubMed
82) Gay F, et al : Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma : updated results. Blood 122 : 1376-1383, 2013
PubMed
83) Garderet L, et al : Upfront autologous stem cell transplantation for newly diagnosed elder ly multiple myeloma patients : a prospective multicenter study. Haematologica 101 : 1390-1397, 2016.
 
84) Gay F, et al : From transplant to novel cellular therapies in multiple myeloma : European Myeloma Network guidelines and future perspectives. Haematologica 103 : 197-211, 2018.
PubMed
85) Palumbo A, et al : Personalized therapy in multiple myeloma according to patient age and vulnerability : a report of the European Myeloma Network (EMN). Blood 118 : 4519-4529, 2011.
PubMed
86) Larocca A, et al : Patient-centered practice in elderly myeloma patients : an overview and consensus from the European Myeloma Network (EMN). Leukemia 32 : 1697-1712, 2018.
PubMed
87) Rodriguez-Manas L & Fried LP : Frailty in the clinical scenario. Lancet 385 : e7-9, 2015.
PubMed
88) Attal M, et al : Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108 : 3289-3294, 2006.
PubMed
89) Spencer A, et al : Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27 : 1788-1793, 2009.
PubMed
90) Morgan GJ, et al : The role of maintenance thalidomide therapy in multiple myeloma : MRC Myeloma IX results and meta-analysis. Blood 119 : 7-15, 2012.
PubMed
91) Palumbo A, et al : Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma : updated results of a randomized controlled trial. Blood 112 : 3107-3114, 2008.
PubMed
92) Wijermans P, et al : Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma : The HOVON 49 Study. J Clin Oncol 28 : 3160-3166, 2010.
PubMed
93) Facon T, et al : Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06) : a randomised trial. Lancet 370 : 1209-1218, 2007.
PubMed
94) Hulin C, et al : Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma : IFM 01/01 Trial. J Clin Oncol 27 : 3664-3670, 2009.
 
95) Waage A, et al : Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116 : 1405-1412, 2010.
 
96) Zweegman S, et al : Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood 127 : 1109-1116, 2016.
PubMed
97) Stewart AK, et al : Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood 126 : 1294-1301, 2015.
PubMed
98) Attal M, et al : Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366 : 1782-1791, 2012.
PubMed
99) McCarthy PL, et al : Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366 : 1770-1781, 2012.
PubMed
100) Palumbo A, et al : Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371 : 895-905, 2014.
PubMed
101) McCarthy PL, et al : Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma : a meta-analysis. J Clin Oncol 35 : 3279-3289, 2017.
PubMed
102) Jackson GH, et al : Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI) : a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20 : 57-73, 2019.
 
103) Palumbo A, et al : Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. N Engl J Med 366 : 1759-1769, 2012.
PubMed
104) Facon T, et al : Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131 : 301-310, 2018.
PubMed
105) NCCN Guidelines(R) Multiple Myeloma, Version 3. 2020 [https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf].
 
106) Goldshmidt H, et al : Bortezomib before and after high-dose therapy in myeloma : long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia 32 : 383-390, 2018.
 
107) Rosinol L, et al : Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma : a PETHEMA/GEM trial. Leukemia 31 : 1922-1927, 2017.
PubMed
108) Chakraborty R, et al : Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia 32 : 712-718, 2018.
 
109) Palumbo A, et al : Bortezomib-Melphalan-Prednisone-Thalidomide followed by maintenance with Bortezomib-Thalidomide compared with Bortezomib-Melphalan-Prednisone for initial treatment of multiple myeloma : a randomized controlled trial. J Clin Oncol 28 : 5101-5109, 2010.
PubMed
110) Mateos MV, et al : Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120 : 2581-2588, 2012.
 
111) Dimopoulos MA, et al : Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomized, placebo-controlled phase 3 trial. Lancet 393 : 253-264, 2019.
PubMed
112) Palumbo A, et al : Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma : a meta-analysis of individual patient data. Lancet Oncol 15 : 333-342, 2014.
PubMed
113) Benboubker L, et al : Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. N Engl J Med 371 : 906-917, 2014.
PubMed
114) Facon T, et al : Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131 : 301-310, 2018.
PubMed
115) Rajkumar SV, et al : Consensus recommendations for the uniform reporting of clinical trials : report of the International Myeloma Workshop Consensus Panel 1. Blood 117 : 4691-4695, 2011.
PubMed
116) Larocca A, et al : How I treat fragile myeloma patients. Blood 126 : 2179-2185, 2015.
 
117) Dimopoulos MA, et al : Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) : a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17 : 27-38, 2016.
 
118) Dimopoulos MA, et al : Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR) : an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18 : 1327-1337, 2017.
 
119) Stewart AK, et al : Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372 : 142-152, 2015.
PubMed
120) Siegel DS, et al : Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol 36 : 728-734, 2018.
 
121) Moreau P, et al : Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A. R. R. O. W.) : interim analysis results of a randomised, phase 3 study. Lancet Oncol 19 : 953-964, 2018.
 
122) Moreau P, et al : Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 374 : 1621-1634, 2016.
PubMed
123) Avet-Loiseau H, et al : Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood 130 : 2610-2618, 2017.
PubMed
124) San Miguel J, et al : Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003) : a randomised, open-label, phase 3 trial. Lancet Oncol 14 : 1055-1066, 2013.
 
125) Dimopoulos MA, et al : Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica 100 : 1327-1333, 2015.
PubMed
126) Richardson PG, et al : Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM) : a randomised, open-label, phase 3 trial. Lancet Oncol 20 : 781-794, 2019.
 
127) Lonial S, et al : Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373 : 621-631, 2015.
 
128) Dimopoulos MA, et al : Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med 379 : 1811-1822, 2018.
PubMed
129) Dimopoulos MA, et al : Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 375 : 1319-1331, 2016.
PubMed
130) Palumbo A, et al : Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 375 : 754-766, 2016.
PubMed
131) Dimopoulos MA, et al : Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma : updated analysis of POLLUX. Haematologica 103 : 2088-2096, 2018.
 
132) Spencer A, et al : Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma : updated analysis of CASTOR. Haematologica 103 : 2079-2087, 2018.
 
133) Mikhael J, et al : A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood 134 : 123-133, 2019.
PubMed
134) San-Miguel JF, et al : Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma : a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15 : 1195-1206, 2014.
 
135) San-Miguel JF, et al : Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial) : a randomised, placebo-controlled, phase 3 trial. Lancet Haematol 3 : e506-515, 2016.
 
136) Kumar S, et al : High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 34 : 161-167, 2004.
PubMed
137) Parrish C, et al : Autologous stem cell transplantation is an effective salvage therapy for primary refractory multiple myeloma. Biol Blood Marrow Transplant 21 : 1330-1334, 2015.
PubMed
138) Cook G, et al : Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma : a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 17 : 1638-1645, 2011.
PubMed
139) Grovdal M, et al : Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Bone Marrow Transplant 50 : 808-812, 2015.
PubMed
140) Cook G, et al : High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]) : a randomised, open-label, phase 3 trial. Lancet Oncol 15 : 874-885, 2014.
 
141) Patriarca F, et al : Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation. Biol Blood Marrow Transplant 24 : 406-409, 2018.
PubMed
142) Kroger N, et al : Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol 148 : 323-331, 2010.
PubMed
143) Kroger N, et al : Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant 48 : 403-407, 2013.
PubMed
144) Deckert J, et al : SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res 20 : 4574-4583, 2014.
PubMed
145) Richardson PG, et al : A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). ASCO meeting 2019, Abstract No 8004, 2019.
 
146) Cho SF, et al : Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma : Potential Uses of BCMA-Based Immunotherapy. Front Immunol 9 : 1821, 2018.
PubMed
147) Trudel S, et al : Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159) : a dose escalation and expansion phase 1 trial. Lancet Oncol 19 : 1641-1653, 2018.
PubMed
148) Jans DA, et al : Inhibitors of nuclear transport. Curr Opin Cell Biol 58 : 50-60, 2019.
PubMed
149) Chari A, et al : Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 381 : 727-738, 2019.
PubMed
150) Kumar S, et al : Efficacy of venetoclax as targeted therapy for relapsed/refractory t (11 ; 14) multiple myeloma. Blood 130 : 2401-2409, 2017.
PubMed
151) Clinicaltrials. gov (2018). NCT02755597 : A study evaluating venetoclax (ABT-199) in multiple myeloma subjects who are receiving bortezomib and dexamethasone as standard therapy. Accessed March 2019.
 
152) Kumar S, et al : A phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 134 (Suppl 1) : 1888, 2019.
 
153) Clinicaltrials. gov (2018). NCT 03539744 : A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (CANOVA). Accessed June 14, 2019.
 
154) Ali SA, et al : T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128 : 1688-1700, 2016.
PubMed
155) Friedman KM, et al : Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignancies by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells. Hum Gene Ther 29 : 585-601, 2018.
PubMed
156) Raje N, et al : Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med 380 : 1726-1737, 2019.
PubMed
157) Barlogie B, et al : Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma : final results of phase III US Intergroup Trial S9321. J Clin Oncol 24 : 929-936, 2006.
PubMed
158) Sobh M, et al : Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe : Trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia 30 : 2047-2054, 2016.
 
159) Crawley C, et al : Reduced-intensity conditioning for myeloma : lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 109 : 3588-3594, 2007.
PubMed
160) Garban F, et al : Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107 : 3474-3480, 2006.
PubMed
161) Lokhorst HM, et al : Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 119 : 6219-6225, 2012.
PubMed
162) Bruno B, et al : A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356 : 1110-1120, 2007.
 
163) Kneppers E, et al : Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible : results of the HOVON 76 Trial. Blood 118 : 2413-2419, 2011.
 
164) Wolschke C, et al : Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD : Results from a phase I/II dose-finding study. Exp Hematol 41 : 134-142, 2013.
 
165) El-Cheikh J, et al : High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica 93 : 455-458, 2008.
PubMed
166) Matuschek C, et al : Effects of Radiotherapy in the treatment of multiple myeloma : a retrospective analysis of a Single Institution. Radiat Oncol 10 : 71, 2015.
PubMed
167) NCCN Guidelines : multiple myeloma Version 3. 2020 (https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf).
 
168) Snowden JA, et al : Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 154 : 76103, 2011.
 
169) Kilciksiz S, et al : A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. ScientificWorldJournal 2012 : 895765, 2012.
PubMed
170) Tsang RW, et al : Solitary plasmacytoma treated with radiotherapy : impact of tumor size on outcome. Int J Radiation Oncology Biol Phys 50 : 113-120, 2001.
 
171) Dispenzieri A, et al : Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 18 : 673-688, 2005.
PubMed
172) Ozsahin M, et al : Outcomes and patterns of failure in solitary plasmacytoma : a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys 64 : 210-217, 2006.
PubMed
173) Durie BG, et al : Reappraisal of plateau phase in myeloma. Lancet 2 : 65-68, 1980.
PubMed
174) Kyle RA, et al : Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78 : 21-33, 2003.
PubMed
175) Garland P, et al : Percutaneous vertebroplasty in multiple myeloma : prospective long-term follow-up in 106 consecutive patients. Ann Hematol 90 : 95-100, 2011.
 
176) Berenson JR, et al : Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer : a multicentre, randomised controlled trial. Lancet Oncol 12 : 225-235, 2011.
 
177) Berenson JR, et al : Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334 : 488-493, 1996.
 
178) Berenson JR, et al : Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91 : 1191-1200, 2001.
PubMed
179) Kumar SK, et al : Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transplant 41 : 1013-1019, 2008.
PubMed
180) Durie BG, et al : Myeloma management guidelines : a consensus report from the Scientic Advisors of the International Myeloma Foundation. Haematol J 4 : 379-398, 2003.
 
181) Lacy MQ, et al : Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81 : 1047-1053, 2006.
 
182) Kyle RA, et al : American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25 : 2464-2472, 2007.
 
183) Morgan GJ, et al : Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX) : secondary outcomes from a randomised controlled trial. Lancet Oncol 12 : 743-752, 2011.
PubMed
184) Morgan GJ, et al : First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX) : a randomised controlled trial. Lancet 376 : 1989-1999, 2010.
 
185) Morgan GJ, et al : Long-term follow-up of MRC Myeloma IX trial : Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res 19 : 6030-6038, 2013.
 
186) Raje N, et al : Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma : an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 19 : 370-381, 2018.
 
187) Anderson K, et al : Role of Bone-Modifying Agents in Multiple Myeloma : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 36 : 812-818, 2018.
 
188) NCCN Guidelines : multiple myeloma Version 3. 2020 (https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf).
 
189) 日本口腔外科学会顎骨壊死検討委員会 : 骨吸収抑制薬関連顎骨壊死の病態と管理 : 顎骨壊死検討委員会ポジションペーパー 2016 [PDF] (https://www.jsoms.or.jp/medical/wp-content/uploads/2015/08/position_paper2016.pdf).
 
190) Bilezikian JP : Management of Acute Hypercalcemia. N Engl J Med 326 : 1196-1203, 1992.
PubMed
191) Raje N, et al : Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma : An International Double-Blind, Double-Dummy, Randomised, Controlled, Phase 3 Study. Lancet Oncol 19 : 370-381, 2018.
 
192) Ozaki S, et al : Trends of Survival in Patients With Multiple Myeloma in Japan : A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma. Blood Cancer J 5 : e349, 2015.
PubMed
193) 麻奥英毅, 他 : 多発性骨髄腫における検査所見. 多発性骨髄腫治療マニュアル, (木崎昌弘編), 南江堂, 58-67, 2012.
 
194) 血液製剤の使用指針. 厚生労働省医薬・生活衛生局, 平成31年3月.
 
195) Bohlius J, et al : Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents : ASCO/ASH Clinical Practice Guideline Update. Blood Adv 3 : 1197-1210, 2019.
PubMed
196) Jimenez-Zepeda VH : Light chain deposition disease : novel biological insights and treatment advances. Int J Lab Hematol 34 : 347-355, 2012.
PubMed
197) Dimopoulos MA, et al : Renal impairment in patients with multiple myeloma : a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28 : 4976-4984, 2010.
 
198) Dimopoulos MA, et al : VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment : cohort analysis of the phase III VISTA study. J Clin Oncol 27 : 6086-6093, 2009.
PubMed
199) Breitkreutz I, et al : Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure. Bone Marrow Transplant 49 : 1371-1375, 2014.
PubMed
200) Dimopoulos MA, et al : The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 27 : 423-429, 2013.
PubMed
201) Dimopoulos M, et al : Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure : a subgroup analysis of ENDEAVOR. Blood 133 : 147-155, 2019.
PubMed
202) Tosi P, et al : Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure. Mediterr J Hematol Infect Dis 5 : e2013037, 2013.
PubMed
203) Richter J, et al : Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction : a case series. Hematol Oncol 35 : 246-251, 2017.
PubMed
204) Hutchison CA, et al : Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant 27 : 3823-3828, 2012.
PubMed
205) Blimark C, et al : Multiple myeloma and infections : a population-based study on 9253 multiple myeloma patients. Haematologica 100 : 107-113, 2015.
 
206) Teh BW, et al : Risks, severity and timing of infections in patients with multiple myeloma : a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol 171 : 100-108, 2015.
PubMed
207) Dimopoulos MA, et al : Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 28 : 1573-1585, 2014.
 
208) Ammann EM, et al : Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. Blood 127 : 200-207, 2016.
PubMed
209) Teh BW, et al : Changing treatment paradigms for patients with plasma cell myeloma : impact upon immune determinants of infection. Blood Rev 28 : 75-86, 2014.
PubMed
210) Teh BW, et al : Risks and burden of viral respiratory tract infection in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib : experience at an Australian Cancer Hospital. Support Care Cancer 23 : 1901-1906, 2015.
PubMed
211) Konig C, et al : Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Hematol 93 : 479-484, 2014.
PubMed
212) Richardson PG, et al : Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26 : 595-608, 2012.
PubMed
213) Delforge M, et al : Treatment-related peripheral neuropathy in multiple myeloma : the challenge continues. Lancet Oncol 11 : 1086-1095, 2010.
PubMed
214) Moreau P, et al : Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma : a randomised, phase 3, non-inferiority study. Lancet Oncol 12 : 431-440, 2011.
PubMed
215) Terpos E, et al : European Myeloma Network guidelines for the management of multiple myeloma related complications. Haematologica 100 : 1254-1266, 2015.
PubMed
216) Sonneveld P, et al : Dealing with neuropathy in plasma-cell dycrasias. Hematology Am Soc Hematol Educ Program 2010 : 423-430, 2010.
 
217) Gerz MA, et al : Hyperviscosity syndrome. J Intensive Cre Med 10 : 128-141, 1995.
 
218) Mehta J, et al : Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost 29 : 467-471, 2003.
PubMed
219) Kyle RA, et al : Treatment of multiple myeloma : a comprehensive review. Clin Lymphoma Myeloma 9 : 278-288, 2009.
PubMed
220) Srkalovic G, et al : Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 101 : 558-566, 2004.
PubMed
221) Palumbo A, et al : International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem cell transplantation. J Clin Oncol 32 : 587-600, 2014.
 

V 類縁疾患

P.83 掲載の参考文献
1) Nakanishi T, et al : The Crow-Fukase syndrome : a study of 102 cases in Japan. Neurology 34 : 712-720, 1984.
PubMed
2) Bardwick PA, et al : Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes : the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore) 59 : 311-322, 1980.
 
3) Suichi T, et al : Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. Neurology 93 : 1-9, 2019.
PubMed
4) Dispenzieri A : 2019 Update on diagnosis, risk-stratification, and management. Am J Hematol 94 : 812-827, 2019.
PubMed
5) Misawa S, et al : Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response : retrospective cohort study. BMJ Open 5 : e009157, 2015.
PubMed
6) Abe D, et al : Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome. Blood 112 : 836-839, 2008.
PubMed
7) Dispenzieri A, et al : Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 104 : 3400-3407, 2004.
 
8) Kawajiri-Manako C, et al : Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome : A Nationwide Survey in Japan. Biol Blood Marrow Transplant 24 : 1180-1186, 2018.
PubMed
9) Ohwada C, et al : Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood 131 : 2173-2176, 2018.
PubMed
10) Misawa S, et al : Safety and efficacy of thalidomide in patients with POEMS syndrome : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 15 : 1129-1137, 2016.
PubMed
11) Li J, et al : A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Am J Hematol 93 : 803-809, 2018.
 
12) He H, et al : Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen. Br J Haematol 181 : 126-128, 2018.
PubMed
13) Kyle RA, et al : Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79 : 1817-1822, 1992.
PubMed
14) Kyle RA, et al : Primary systemic amyloidosis : multivariate analysis for prognostic factors in 168 cases. Blood 68 : 220-224, 1986.
PubMed
15) Mumford AD, et al : Bleeding symptoms and coagulation abnormalities in 337 patients with AL amyloidosis. Br J Haematol 110 : 454-460, 2000.
PubMed
16) Gertz MA, et al : Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL) : a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79 : 319-328, 2005.
PubMed
17) Vaxman I, et al : Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis. Acta Haematol 141 : 93-106, 2019.
PubMed
18) Dispenzieri A, et al : Treatment of immunoglobulin light chain amyloidosis : Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Mayo Clin Proc 90 : 1054-1081, 2015.
PubMed
19) Gertz MA, et al : Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant 48 : 557-561, 2013.
PubMed
20) Perfetti V, et al : Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica 91 : 1635-1643, 2006.
PubMed
21) Palladini G, et al : Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis : long term results of a risk-adapted approach. Haematologica 99 : 743-750, 2014.
PubMed
22) Kastritis E, et al : Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 92 : 1351-1358, 2007.
PubMed
23) Palladini G, et al : A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in up-front treatment of systemic AL amyloidosis. Blood 126 : 612-615, 2015.
 
24) Palladini G, et al : New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers : Impact on survival outcomes. J Clin Oncol 30 : 4541-4549, 2012.
PubMed
25) Sher T, et al : Evolution of hematopoietic cell transplantation for immunoglobulin light chain amyloidosis. Biol Blood Marrow Transplant 22 : 769-801, 2016.
 
26) Kumar S, et al : Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30 : 989-995, 2012.
PubMed
27) Leung N, et al : Monoclonal gammopathy of renal significance : when MGUS is no longer undetermined or insignificant. Blood 120 : 4292-4295, 2012.
 
28) Leung N, et al : The evaluation of monoclonal gammopathy of renal significance : a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 15 : 45-59, 2019.
 
29) Bridoux F, et al : Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 87 : 698-711, 2015.
PubMed
30) Naderi N, et al : Lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia. Arch Pathol Lab Med 137 : 580-585, 2013.
PubMed
31) Rossi D : Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis. Hematology Am Soc Hematol Educ Program 2014 : 113-118, 2014.
PubMed
32) Wang H, et al : Temporal and geographic variations of Waldenstrom macroglobulinemia incidence : a large population-based study. Cancer 118 : 3793-3800, 2012.
PubMed
33) Treon SP, et al : MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 367 : 826-833, 2012.
PubMed
34) Treon SP, et al : Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 123 : 2791-2796, 2014.
PubMed
35) Nguyen-Khac F, et al : Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia. Haematologica 98 : 649-654, 2013.
 
36) Dimopoulos MA, et al : Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders : IWWM-7 consensus. Blood 124 : 1404-1411, 2014.
PubMed
37) Morel P, et al : International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113 : 4163-4170, 2009.
PubMed
38) Leblond V, et al : Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia. Blood 128 : 1321-1328, 2016.
PubMed
39) NCCN Clinical Practice Guidelines in Oncology, Version 1. 2020, Waldenstrom macroglobulinemia/Lymphoplasmacytic Lymphoma.
 
40) Treon SP : How I treat Waldenstrom macroglobulinemia. Blood 126 : 721-732, 2015.
 
41) Dimopoulos MA, et al : Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25 : 3344-3349, 2007.
PubMed
42) D'Souza A, et al : Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma) : a single-center experience. Blood 120 : 56-62, 2012.
PubMed
43) Dimopoulos MA, et al : Waldenstrom's macroglobulinemia : a clinical perspective in the era of novel therapeutics. Ann Oncol 27 : 233-240, 2016.
 
44) Treon SP, et al : Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med 372 : 1430-1440, 2015.
PubMed

資料編

P.117 掲載の参考文献
1) Shimizu K, et al : Management of patients with multiple myeloma in Japan：data of 1,383 patients from 16 hospitals and 1 treatment group. Leuk Lymphoma 45 : 2465-2469, 2004.
PubMed
2) Ozaki S, et al : Trends of survival in patients with multiple myeloma in Japan : a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J 5 : e349, 2015.
PubMed
3) Ozaki S, et al : Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. Ann Hematol 98 : 1703-1711, 2019.
PubMed

書評

最近チェックした商品履歴

Loading...